Drug Watch: What's Coming in the Rosacea Pipeline

Stocum,Linda;

General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Publication

Video

March 10, 2022

Dermatology Times

Dermatology Times, April 2022 (Vol. 43. No. 4)

Volume 43

Issue 4

Pages: 23

Drug Watch: What's Coming in the Rosacea Pipeline

Author(s):

Linda Stocum, Associate Editor

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, chair of dermatology at the University of California-San Diego, in San Diego, California, about what's happening in the rosacea drug pipeline. In this video interview, Gallo talks about what's new in treatment, how certain rosacea phenotypes are harder to treat than others, and what is being done to addresss these issues.

Download Issue PDF

Articles in this issue